Thriva is a technology company.
Thriva has raised $7.0M across 2 funding rounds.
Thriva has raised $7.0M in total across 2 funding rounds.
Thriva is a healthtech startup founded in 2016 that provides at-home blood testing subscriptions, delivering personalized health insights, diagnostics, and actionable recommendations to empower proactive health management.[2][3] It serves consumers seeking to optimize energy, fitness, longevity, or overall vitality, while also offering B2B solutions to entities like the NHS and insurers, solving the problem of inaccessible, preventative health monitoring by enabling real-time tracking to prevent issues before they require hospitalization.[2][3] With over 200,000 customers supported, Thriva combines a user-friendly app, autodraw blood collection device, and doctor-reviewed reports for ongoing progress tracking, demonstrating strong growth in the direct-to-consumer health space.[3][4]
Thriva was founded in 2016 (with roots tracing to 2015) by Hamish Grierson, driven by his personal fascination with health that began 11 years prior, leading him into self-improvement and developing tools for sustained energy and productivity.[2][3] This "rabbit hole" of health optimization inspired a platform for upstream, preventative care through at-home blood testing, shifting from reactive hospital visits to real-time personal insights.[2] Early traction built on a subscription model, evolving to include AI-driven personalization, a MHRA-registered Class One medical device for automated recommendations, and B2B integrations, marking pivotal moments in scaling from consumer-facing tests to enterprise partnerships.[2]
(Note: Thriva Technologies in search result [1] appears to be a distinct entity focused on digital content services, unrelated to this healthtech company.[1])
Thriva rides the wave of preventative healthtech and personalized medicine, fueled by post-pandemic demand for at-home diagnostics, AI advancements, and consumer shift toward data-driven wellness over reactive care.[2][3] Timing aligns with wearable tech limitations—smartwatches track surface metrics, but Thriva's blood analysis provides deeper, "articulate" internal truths, validated by extensive studies.[4] Favorable market forces include rising longevity focus, athlete-inspired optimization for everyday users, and regulatory nods like MHRA approval, positioning Thriva to influence ecosystems by powering public health (NHS) and insurance while normalizing proactive testing for 200,000+ users.[2][3]
Thriva is poised to expand its AI personalization and B2B footprint, potentially integrating deeper with wearables or expanding test profiles amid booming demand for longevity and peak performance tools.[2][4] Trends like computational health advances and regulatory easing for home devices will accelerate growth, evolving Thriva from a subscription pioneer to a core platform in everyday health empowerment—keeping its founding promise of upstream prevention alive in a vitality-obsessed world.[2][3]
Thriva has raised $7.0M in total across 2 funding rounds.
Thriva's investors include Atomico, DST Global, Mosaic Ventures, Target Global, Errol Damelin, Paul Forster, 01 Advisors, Andreessen Horowitz, Coatue, Contrary Capital, DCM, Energize Ventures.
Thriva has raised $7.0M across 2 funding rounds. Most recently, it raised $5.0M Series A in May 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2020 | $5.0M Series A | Atomico, DST Global, Mosaic Ventures, Target Global, Errol Damelin, Paul Forster | |
| Jun 1, 2017 | $2.0M Seed | 01 Advisors, Andreessen Horowitz, Coatue, Contrary Capital, DCM, Energize Ventures, Entrepreneur First, Episode 1 Ventures, Felicis Ventures, Felix Capital, Floodgate, LGF, Liquid 2 Ventures, Long Journey Ventures, Octopus Ventures, Outrun Ventures, Pareto Holdings, Project A, TDK Ventures, Voyager Ventures, Wave Capital, Andrew Robb, John Johnson, Nic Brisbourne, Ron Pragides, Ryan Orr, Will Brooks |